Jacobs Levy Equity Management Inc. Has $1.35 Million Position in AxoGen, Inc. (NASDAQ:AXGN)

Jacobs Levy Equity Management Inc. lifted its stake in AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 39.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 82,000 shares of the medical equipment provider's stock after acquiring an additional 23,070 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.19% of AxoGen worth $1,351,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Sei Investments Co. bought a new position in shares of AxoGen during the 4th quarter worth approximately $188,000. New York State Common Retirement Fund lifted its stake in AxoGen by 63.7% during the fourth quarter. New York State Common Retirement Fund now owns 69,629 shares of the medical equipment provider's stock worth $1,147,000 after purchasing an additional 27,101 shares during the last quarter. Renaissance Technologies LLC bought a new stake in AxoGen during the fourth quarter worth $363,000. Dimensional Fund Advisors LP lifted its stake in AxoGen by 13.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 772,752 shares of the medical equipment provider's stock worth $12,735,000 after purchasing an additional 91,984 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its stake in shares of AxoGen by 8.3% in the 4th quarter. Principal Financial Group Inc. now owns 16,000 shares of the medical equipment provider's stock valued at $264,000 after acquiring an additional 1,228 shares during the last quarter. Institutional investors and hedge funds own 80.29% of the company's stock.

AxoGen Trading Down 1.8%

NASDAQ AXGN traded down $0.21 on Thursday, reaching $11.20. The company had a trading volume of 104,822 shares, compared to its average volume of 463,451. The firm has a market cap of $509.87 million, a price-to-earnings ratio of -35.05 and a beta of 1.19. AxoGen, Inc. has a fifty-two week low of $6.01 and a fifty-two week high of $21.00. The business has a 50 day moving average of $15.79 and a two-hundred day moving average of $16.17. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47.

Insider Activity at AxoGen

In other AxoGen news, Director Amy Mcbride Wendell sold 5,000 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $20.02, for a total transaction of $100,100.00. Following the completion of the sale, the director now directly owns 97,899 shares in the company, valued at approximately $1,959,937.98. This trade represents a 4.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Erick Wayne Devinney sold 15,111 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total value of $264,442.50. Following the sale, the insider now owns 217,762 shares of the company's stock, valued at approximately $3,810,835. The trade was a 6.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.78% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on AXGN shares. Canaccord Genuity Group dropped their price target on AxoGen from $26.00 to $24.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Cantor Fitzgerald restated an "overweight" rating and issued a $24.00 price objective on shares of AxoGen in a report on Wednesday, March 5th. Finally, Lake Street Capital assumed coverage on AxoGen in a report on Monday, March 17th. They issued a "buy" rating and a $30.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $22.20.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.